{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,18]],"date-time":"2026-05-18T12:30:23Z","timestamp":1779107423879,"version":"3.51.4"},"reference-count":129,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2024,8,31]],"date-time":"2024-08-31T00:00:00Z","timestamp":1725062400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2024,8,31]],"date-time":"2024-08-31T00:00:00Z","timestamp":1725062400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Discov Onc"],"DOI":"10.1007\/s12672-024-01245-0","type":"journal-article","created":{"date-parts":[[2024,8,31]],"date-time":"2024-08-31T09:02:16Z","timestamp":1725094936000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":8,"title":["Glutamine and leukemia research: progress and clinical prospects"],"prefix":"10.1007","volume":"15","author":[{"given":"Zexin","family":"Wang","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Miao","family":"Liu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Qiang","family":"Yang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2024,8,31]]},"reference":[{"key":"1245_CR1","doi-asserted-by":"publisher","first-page":"16","DOI":"10.6004\/jnccn.2021.0002","volume":"19","author":"DA Pollyea","year":"2021","unstructured":"Pollyea DA, Bixby D, Perl A, Bhatt VR, Altman JK, Appelbaum FR, de Lima M, Fathi AT, Foran JM, Gojo I, Hall AC, Jacoby M, Lancet J, Mannis G, Marcucci G, Martin MG, Mims A, Neff J, Nejati R, Olin R, Percival M-E, Prebet T, Przespolewski A, Rao D, Ravandi-Kashani F, Shami PJ, Stone RM, Strickland SA, Sweet K, Vachhani P, Wieduwilt M, Gregory KM, Ogba N, Tallman MS. NCCN guidelines insights: acute myeloid leukemia, Version 2.2021. J Natl Compr Cancer Netw JNCCN. 2021;19:16\u201327. https:\/\/doi.org\/10.6004\/jnccn.2021.0002.","journal-title":"J Natl Compr Cancer Netw JNCCN"},{"key":"1245_CR2","doi-asserted-by":"publisher","first-page":"88","DOI":"10.1186\/s13045-022-01308-1","volume":"15","author":"X Jin","year":"2022","unstructured":"Jin X, Zhang M, Sun R, Lyu H, Xiao X, Zhang X, Li F, Xie D, Xiong X, Wang J, Lu W, Zhang H, Zhao M. First-in-human phase I study of CLL-1 CAR-T cells in adults with relapsed\/refractory acute myeloid leukemia. J Hematol OncolJ Hematol Oncol. 2022;15:88. https:\/\/doi.org\/10.1186\/s13045-022-01308-1.","journal-title":"J Hematol OncolJ Hematol Oncol"},{"key":"1245_CR3","doi-asserted-by":"publisher","first-page":"184","DOI":"10.1038\/mt.2014.164","volume":"23","author":"Q Wang","year":"2015","unstructured":"Wang Q, Wang Y, Lv H, Han Q, Fan H, Guo B, Wang L, Han W. Treatment of CD33-directed chimeric antigen receptor-modified T cells in one patient with relapsed and refractory acute myeloid leukemia. Mol Ther. 2015;23:184\u201391. https:\/\/doi.org\/10.1038\/mt.2014.164.","journal-title":"Mol Ther"},{"key":"1245_CR4","doi-asserted-by":"publisher","first-page":"7542","DOI":"10.3390\/ijms23147542","volume":"23","author":"M Gallazzi","year":"2022","unstructured":"Gallazzi M, Ucciero MAM, Faraci DG, Mahmoud AM, Al Essa W, Gaidano G, Mouhssine S, Cris\u00e0 E. New frontiers in monoclonal antibodies for the targeted therapy of acute myeloid leukemia and myelodysplastic syndromes. Int J Mol Sci. 2022;23:7542. https:\/\/doi.org\/10.3390\/ijms23147542.","journal-title":"Int J Mol Sci"},{"key":"1245_CR5","doi-asserted-by":"publisher","first-page":"2249","DOI":"10.3390\/cells11142249","volume":"11","author":"Y Abaza","year":"2022","unstructured":"Abaza Y, Zeidan AM. Immune checkpoint inhibition in acute myeloid leukemia and myelodysplastic syndromes. Cells. 2022;11:2249. https:\/\/doi.org\/10.3390\/cells11142249.","journal-title":"Cells"},{"key":"1245_CR6","doi-asserted-by":"publisher","first-page":"1459","DOI":"10.1038\/s41591-020-0910-8","volume":"26","author":"C Riether","year":"2020","unstructured":"Riether C, Pabst T, H\u00f6pner S, Bacher U, Hinterbrandner M, Banz Y, M\u00fcller R, Manz MG, Gharib WH, Francisco D, Bruggmann R, van Rompaey L, Moshir M, Delahaye T, Gandini D, Erzeel E, Hultberg A, Fung S, de Haard H, Leupin N, Ochsenbein AF. Targeting CD70 with cusatuzumab eliminates acute myeloid leukemia stem cells in patients treated with hypomethylating agents. Nat Med. 2020;26:1459\u201367. https:\/\/doi.org\/10.1038\/s41591-020-0910-8.","journal-title":"Nat Med"},{"key":"1245_CR7","doi-asserted-by":"publisher","first-page":"1056648","DOI":"10.3389\/fnut.2022.1056648","volume":"9","author":"H Zhou","year":"2022","unstructured":"Zhou H, Wang F, Niu T. Prediction of prognosis and immunotherapy response of amino acid metabolism genes in acute myeloid leukemia. Front Nutr. 2022;9:1056648. https:\/\/doi.org\/10.3389\/fnut.2022.1056648.","journal-title":"Front Nutr"},{"key":"1245_CR8","doi-asserted-by":"publisher","first-page":"4079","DOI":"10.1158\/1078-0432.CCR-18-3223","volume":"25","author":"MA Gregory","year":"2019","unstructured":"Gregory MA, Nemkov T, Park HJ, Zaberezhnyy V, Gehrke S, Adane B, Jordan CT, Hansen KC, D\u2019Alessandro A, DeGregori J. Targeting glutamine metabolism and redox state for leukemia therapy. Clin Cancer Res Off J Am Assoc Cancer Res. 2019;25:4079\u201390. https:\/\/doi.org\/10.1158\/1078-0432.CCR-18-3223.","journal-title":"Clin Cancer Res Off J Am Assoc Cancer Res"},{"key":"1245_CR9","doi-asserted-by":"publisher","first-page":"163","DOI":"10.1146\/annurev-bioeng-071516-044546","volume":"19","author":"L Yang","year":"2017","unstructured":"Yang L, Venneti S, Nagrath D. Glutaminolysis: a hallmark of cancer metabolism. Annu Rev Biomed Eng. 2017;19:163\u201394. https:\/\/doi.org\/10.1146\/annurev-bioeng-071516-044546.","journal-title":"Annu Rev Biomed Eng"},{"key":"1245_CR10","doi-asserted-by":"publisher","first-page":"E117","DOI":"10.1152\/ajpendo.1986.251.1.E117","volume":"251","author":"D Darmaun","year":"1986","unstructured":"Darmaun D, Matthews DE, Bier DM. Glutamine and glutamate kinetics in humans. Am J Physiol. 1986;251:E117-126. https:\/\/doi.org\/10.1152\/ajpendo.1986.251.1.E117.","journal-title":"Am J Physiol"},{"key":"1245_CR11","doi-asserted-by":"publisher","first-page":"530","DOI":"10.1080\/10428194.2021.1992759","volume":"63","author":"MR Rex","year":"2022","unstructured":"Rex MR, Williams R, Birsoy K, Ta Llman MS, Stahl M. Targeting mitochondrial metabolism in acute myeloid leukemia. Leuk Lymphoma. 2022;63:530\u20137. https:\/\/doi.org\/10.1080\/10428194.2021.1992759.","journal-title":"Leuk Lymphoma"},{"key":"1245_CR12","doi-asserted-by":"publisher","first-page":"1113228","DOI":"10.3389\/fnut.2023.1113228","volume":"10","author":"M Wang","year":"2023","unstructured":"Wang M, Zhao A, Li M, Niu T. Amino acids in hematologic malignancies: current status and future perspective. Front Nutr. 2023;10:1113228. https:\/\/doi.org\/10.3389\/fnut.2023.1113228.","journal-title":"Front Nutr"},{"key":"1245_CR13","doi-asserted-by":"publisher","first-page":"1269","DOI":"10.1182\/blood-2015-07-659508","volume":"126","author":"A Emadi","year":"2015","unstructured":"Emadi A. Exploiting AML vulnerability: glutamine dependency. Blood. 2015;126:1269\u201370. https:\/\/doi.org\/10.1182\/blood-2015-07-659508.","journal-title":"Blood"},{"key":"1245_CR14","doi-asserted-by":"publisher","first-page":"175","DOI":"10.1002\/(SICI)1097-4652(199610)169:1<175::AID-JCP18>3.0.CO;2-C","volume":"169","author":"PG Petronini","year":"1996","unstructured":"Petronini PG, Urbani S, Alfieri R, Borghetti AF, Guidotti GG. Cell susceptibility to apoptosis by glutamine deprivation and rescue: survival and apoptotic death in cultured lymphoma-leukemia cell lines. J Cell Physiol. 1996;169:175\u201385. https:\/\/doi.org\/10.1002\/(SICI)1097-4652(199610)169:1%3c175::AID-JCP18%3e3.0.CO;2-C.","journal-title":"J Cell Physiol"},{"key":"1245_CR15","doi-asserted-by":"publisher","first-page":"364","DOI":"10.1038\/nature11706","volume":"491","author":"A Schulze","year":"2012","unstructured":"Schulze A, Harris AL. How cancer metabolism is tuned for proliferation and vulnerable to disruption. Nature. 2012;491:364\u201373. https:\/\/doi.org\/10.1038\/nature11706.","journal-title":"Nature"},{"key":"1245_CR16","doi-asserted-by":"publisher","first-page":"355","DOI":"10.3390\/jcm8030355","volume":"8","author":"SK Saha","year":"2019","unstructured":"Saha SK, Islam SMR, Abdullah-AL-Wadud M, Islam S, Ali F, Park KS. Multiomics analysis reveals that GLS and GLS2 differentially modulate the clinical outcomes of cancer. J Clin Med. 2019;8:355. https:\/\/doi.org\/10.3390\/jcm8030355.","journal-title":"J Clin Med"},{"key":"1245_CR17","doi-asserted-by":"publisher","first-page":"7455","DOI":"10.1073\/pnas.1001006107","volume":"107","author":"W Hu","year":"2010","unstructured":"Hu W, Zhang C, Wu R, Sun Y, Levine A, Feng Z. Glutaminase 2, a novel p53 target gene regulating energy metabolism and antioxidant function. Proc Natl Acad Sci USA. 2010;107:7455\u201360. https:\/\/doi.org\/10.1073\/pnas.1001006107.","journal-title":"Proc Natl Acad Sci USA"},{"key":"1245_CR18","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1038\/358015a0","volume":"358","author":"DP Lane","year":"1992","unstructured":"Lane DP. Cancer. p53, guardian of the genome. Nature. 1992;358:15\u20136. https:\/\/doi.org\/10.1038\/358015a0.","journal-title":"Nature"},{"key":"1245_CR19","doi-asserted-by":"publisher","first-page":"7461","DOI":"10.1073\/pnas.1002459107","volume":"107","author":"S Suzuki","year":"2010","unstructured":"Suzuki S, Tanaka T, Poyurovsky MV, Nagano H, Mayama T, Ohkubo S, Lokshin M, Hosokawa H, Nakayama T, Suzuki Y, Sugano S, Sato E, Nagao T, Yokote K, Tatsuno I, Prives C. Phosphate-activated glutaminase (GLS2), a p53-inducible regulator of glutamine metabolism and reactive oxygen species. Proc Natl Acad Sci USA. 2010;107:7461\u20136. https:\/\/doi.org\/10.1073\/pnas.1002459107.","journal-title":"Proc Natl Acad Sci USA"},{"key":"1245_CR20","doi-asserted-by":"publisher","first-page":"1395","DOI":"10.4161\/cc.24478","volume":"12","author":"A Giacobbe","year":"2013","unstructured":"Giacobbe A, Bongiorno-Borbone L, Bernassola F, Terrinoni A, Markert EK, Levine AJ, Feng Z, Agostini M, Zolla L, Agr\u00f2 AF, Notterman DA, Melino G, Peschiaroli A. p63 regulates glutaminase 2 expression. Cell Cycle. 2013;12:1395\u2013405. https:\/\/doi.org\/10.4161\/cc.24478.","journal-title":"Cell Cycle"},{"key":"1245_CR21","doi-asserted-by":"publisher","first-page":"3564","DOI":"10.4161\/cc.26771","volume":"12","author":"T Velletri","year":"2013","unstructured":"Velletri T, Romeo F, Tucci P, Peschiaroli A, Annicchiarico-Petruzzelli M, Niklison-Chirou MV, Amelio I, Knight RA, Mak TW, Melino G, Agostini M. GLS2 is transcriptionally regulated by p73 and contributes to neuronal differentiation. Cell Cycle. 2013;12:3564\u201373. https:\/\/doi.org\/10.4161\/cc.26771.","journal-title":"Cell Cycle"},{"key":"1245_CR22","doi-asserted-by":"publisher","first-page":"18697","DOI":"10.1073\/pnas.1415669112","volume":"111","author":"C-L Hung","year":"2014","unstructured":"Hung C-L, Wang L-Y, Yu Y-L, Chen H-W, Srivastava S, Petrovics G, Kung H-J. A long noncoding RNA connects c-Myc to tumor metabolism. Proc Natl Acad Sci USA. 2014;111:18697\u2013702. https:\/\/doi.org\/10.1073\/pnas.1415669112.","journal-title":"Proc Natl Acad Sci USA"},{"key":"1245_CR23","doi-asserted-by":"publisher","first-page":"762","DOI":"10.1038\/nature07823","volume":"458","author":"P Gao","year":"2009","unstructured":"Gao P, Tchernyshyov I, Chang T-C, Lee Y-S, Kita K, Ochi T, Zeller K, De Marzo AM, Van Eyk JE, Mendell JT, Dang CV. c-Myc suppression of miR-23 enhances mitochondrial glutaminase and glutamine metabolism. Nature. 2009;458:762\u20135. https:\/\/doi.org\/10.1038\/nature07823.","journal-title":"Nature"},{"key":"1245_CR24","doi-asserted-by":"publisher","DOI":"10.1016\/j.bcmd.2020.102422","volume":"88","author":"F Dernie","year":"2021","unstructured":"Dernie F. Characterisation of a mitochondrial glutamine transporter provides a new opportunity for targeting glutamine metabolism in acute myeloid leukaemia. Blood Cells Mol Dis. 2021;88: 102422. https:\/\/doi.org\/10.1016\/j.bcmd.2020.102422.","journal-title":"Blood Cells Mol Dis"},{"key":"1245_CR25","doi-asserted-by":"publisher","first-page":"2877","DOI":"10.1074\/jbc.RA117.001342","volume":"293","author":"Y Cormerais","year":"2018","unstructured":"Cormerais Y, Massard PA, Vucetic M, Giuliano S, Tambutt\u00e9 E, Durivault J, Vial V, Endou H, Wempe MF, Parks SK, Pouyssegur J. The glutamine transporter ASCT2 (SLC1A5) promotes tumor growth independently of the amino acid transporter LAT1 (SLC7A5). J Biol Chem. 2018;293:2877\u201387. https:\/\/doi.org\/10.1074\/jbc.RA117.001342.","journal-title":"J Biol Chem"},{"key":"1245_CR26","doi-asserted-by":"publisher","first-page":"447","DOI":"10.1007\/s00280-020-04218-6","volume":"87","author":"E Teixeira","year":"2021","unstructured":"Teixeira E, Silva C, Martel F. The role of the glutamine transporter ASCT2 in antineoplastic therapy. Cancer Chemother Pharmacol. 2021;87:447\u201364. https:\/\/doi.org\/10.1007\/s00280-020-04218-6.","journal-title":"Cancer Chemother Pharmacol"},{"key":"1245_CR27","doi-asserted-by":"publisher","first-page":"390","DOI":"10.1038\/s42255-019-0039-6","volume":"1","author":"F Ni","year":"2019","unstructured":"Ni F, Yu W-M, Li Z, Graham DK, Jin L, Kang S, Rossi MR, Li S, Broxmeyer HE, Qu C-K. Critical role of ASCT2-mediated amino acid metabolism in promoting leukaemia development and progression. Nat Metab. 2019;1:390\u2013403. https:\/\/doi.org\/10.1038\/s42255-019-0039-6.","journal-title":"Nat Metab"},{"key":"1245_CR28","doi-asserted-by":"publisher","first-page":"194","DOI":"10.1038\/nm.4464","volume":"24","author":"ML Schulte","year":"2018","unstructured":"Schulte ML, Fu A, Zhao P, Li J, Geng L, Smith ST, Kondo J, Coffey RJ, Johnson MO, Rathmell JC, Sharick JT, Skala MC, Smith JA, Berlin J, Washington MK, Nickels ML, Manning HC. Pharmacological blockade of ASCT2-dependent glutamine transport leads to anti-tumor efficacy in preclinical models. Nat Med. 2018;24:194\u2013202. https:\/\/doi.org\/10.1038\/nm.4464.","journal-title":"Nat Med"},{"key":"1245_CR29","first-page":"6006","volume":"7","author":"F Huang","year":"2014","unstructured":"Huang F, Zhao Y, Zhao J, Wu S, Jiang Y, Ma H, Zhang T. Upregulated SLC1A5 promotes cell growth and survival in colorectal cancer. Int J Clin Exp Pathol. 2014;7:6006\u201314.","journal-title":"Int J Clin Exp Pathol"},{"key":"1245_CR30","doi-asserted-by":"publisher","first-page":"560","DOI":"10.1158\/1078-0432.CCR-12-2334","volume":"19","author":"M Hassanein","year":"2013","unstructured":"Hassanein M, Hoeksema MD, Shiota M, Qian J, Harris BK, Chen H, Clark JE, Alborn WE, Eisenberg R, Massion PP. SLC1A5 mediates glutamine transport required for lung cancer cell growth and survival. Clin Cancer Res Off J Am Assoc Cancer Res. 2013;19:560\u201370. https:\/\/doi.org\/10.1158\/1078-0432.CCR-12-2334.","journal-title":"Clin Cancer Res Off J Am Assoc Cancer Res"},{"key":"1245_CR31","doi-asserted-by":"publisher","first-page":"278","DOI":"10.1002\/path.4518","volume":"236","author":"Q Wang","year":"2015","unstructured":"Wang Q, Hardie R-A, Hoy AJ, van Geldermalsen M, Gao D, Fazli L, Sadowski MC, Balaban S, Schreuder M, Nagarajah R, Wong JJ-L, Metierre C, Pinello N, Otte NJ, Lehman ML, Gleave M, Nelson CC, Bailey CG, Ritchie W, Rasko JEJ, Holst J. Targeting ASCT2-mediated glutamine uptake blocks prostate cancer growth and tumour development. J Pathol. 2015;236:278\u201389. https:\/\/doi.org\/10.1002\/path.4518.","journal-title":"J Pathol"},{"key":"1245_CR32","doi-asserted-by":"publisher","first-page":"1175","DOI":"10.1007\/s12253-015-9954-3","volume":"21","author":"O Nikkuni","year":"2015","unstructured":"Nikkuni O, Kaira K, Toyoda M, Shino M, Sakakura K, Takahashi K, Tominaga H, Oriuchi N, Suzuki M, Iijima M, Asao T, Nishiyama M, Nagamori S, Kanai Y, Oyama T, Chikamatsu K. Expression of amino acid transporters (LAT1 and ASCT2) in patients with stage III\/IV laryngeal squamous cell carcinoma. Pathol Oncol Res POR. 2015;21:1175\u201381. https:\/\/doi.org\/10.1007\/s12253-015-9954-3.","journal-title":"Pathol Oncol Res POR"},{"key":"1245_CR33","doi-asserted-by":"publisher","first-page":"381","DOI":"10.1002\/jso.24160","volume":"113","author":"H Honjo","year":"2016","unstructured":"Honjo H, Kaira K, Miyazaki T, Yokobori T, Kanai Y, Nagamori S, Oyama T, Asao T, Kuwano H. Clinicopathological significance of LAT1 and ASCT2 in patients with surgically resected esophageal squamous cell carcinoma. J Surg Oncol. 2016;113:381\u20139. https:\/\/doi.org\/10.1002\/jso.24160.","journal-title":"J Surg Oncol"},{"key":"1245_CR34","doi-asserted-by":"publisher","first-page":"90","DOI":"10.1002\/path.4429","volume":"235","author":"P Ren","year":"2015","unstructured":"Ren P, Yue M, Xiao D, Xiu R, Gan L, Liu H, Qing G. ATF4 and N-Myc coordinate glutamine metabolism in MYCN-amplified neuroblastoma cells through ASCT2 activation. J Pathol. 2015;235:90\u2013100. https:\/\/doi.org\/10.1002\/path.4429.","journal-title":"J Pathol"},{"key":"1245_CR35","doi-asserted-by":"publisher","first-page":"821","DOI":"10.1007\/s00432-018-2605-9","volume":"144","author":"J Ye","year":"2018","unstructured":"Ye J, Huang Q, Xu J, Huang J, Wang J, Zhong W, Chen W, Lin X, Lin X. Targeting of glutamine transporter ASCT2 and glutamine synthetase suppresses gastric cancer cell growth. J Cancer Res Clin Oncol. 2018;144:821\u201333. https:\/\/doi.org\/10.1007\/s00432-018-2605-9.","journal-title":"J Cancer Res Clin Oncol"},{"key":"1245_CR36","doi-asserted-by":"publisher","first-page":"BSR20212171","DOI":"10.1042\/BSR20212171","volume":"42","author":"W Wang","year":"2022","unstructured":"Wang W, Pan H, Ren F, Chen H, Ren P. Targeting ASCT2-mediated glutamine metabolism inhibits proliferation and promotes apoptosis of pancreatic cancer cells. Biosci Rep. 2022;42:BSR20212171. https:\/\/doi.org\/10.1042\/BSR20212171.","journal-title":"Biosci Rep"},{"key":"1245_CR37","doi-asserted-by":"publisher","first-page":"667","DOI":"10.1148\/radiol.2017162610","volume":"287","author":"MPS Dunphy","year":"2018","unstructured":"Dunphy MPS, Harding JJ, Venneti S, Zhang H, Burnazi EM, Bromberg J, Omuro AM, Hsieh JJ, Mellinghoff IK, Staton K, Pressl C, Beattie BJ, Zanzonico PB, Gerecitano JF, Kelsen DP, Weber W, Lyashchenko SK, Kung HF, Lewis JS. In vivo PET assay of tumor glutamine flux and metabolism: in-human trial of 18F-(2S,4R)-4-fluoroglutamine. Radiology. 2018;287:667\u201375. https:\/\/doi.org\/10.1148\/radiol.2017162610.","journal-title":"Radiology"},{"key":"1245_CR38","doi-asserted-by":"publisher","first-page":"3201","DOI":"10.1038\/onc.2015.381","volume":"35","author":"M van Geldermalsen","year":"2016","unstructured":"van Geldermalsen M, Wang Q, Nagarajah R, Marshall AD, Thoeng A, Gao D, Ritchie W, Feng Y, Bailey CG, Deng N, Harvey K, Beith JM, Selinger CI, O\u2019Toole SA, Rasko JEJ, Holst J. ASCT2\/SLC1A5 controls glutamine uptake and tumour growth in triple-negative basal-like breast cancer. Oncogene. 2016;35:3201\u20138. https:\/\/doi.org\/10.1038\/onc.2015.381.","journal-title":"Oncogene"},{"key":"1245_CR39","doi-asserted-by":"publisher","first-page":"1136","DOI":"10.1056\/NEJMra1406184","volume":"373","author":"H D\u00f6hner","year":"2015","unstructured":"D\u00f6hner H, Weisdorf DJ, Bloomfield CD. Acute myeloid leukemia. N Engl J Med. 2015;373:1136\u201352. https:\/\/doi.org\/10.1056\/NEJMra1406184.","journal-title":"N Engl J Med"},{"key":"1245_CR40","doi-asserted-by":"publisher","first-page":"3928","DOI":"10.3390\/ijms21113928","volume":"21","author":"C Panuzzo","year":"2020","unstructured":"Panuzzo C, Jovanovski A, Pergolizzi B, Pironi L, Stanga S, Fava C, Cilloni D. Mitochondria: a galaxy in the hematopoietic and leukemic stem cell universe. Int J Mol Sci. 2020;21:3928. https:\/\/doi.org\/10.3390\/ijms21113928.","journal-title":"Int J Mol Sci"},{"key":"1245_CR41","doi-asserted-by":"publisher","first-page":"22","DOI":"10.1186\/s41241-017-0022-z","volume":"37","author":"SE S\u00e1nchez-Mendoza","year":"2017","unstructured":"S\u00e1nchez-Mendoza SE, Rego EM. Targeting the mitochondria in acute myeloid leukemia. Appl Cancer Res. 2017;37:22. https:\/\/doi.org\/10.1186\/s41241-017-0022-z.","journal-title":"Appl Cancer Res"},{"key":"1245_CR42","doi-asserted-by":"publisher","first-page":"225","DOI":"10.1016\/j.ccr.2010.01.020","volume":"17","author":"PS Ward","year":"2010","unstructured":"Ward PS, Patel J, Wise DR, Abdel-Wahab O, Bennett BD, Coller HA, Cross JR, Fantin VR, Hedvat CV, Perl AE, Rabinowitz JD, Carroll M, Su SM, Sharp KA, Levine RL, Thompson CB. The common feature of leukemia-associated IDH1 and IDH2 mutations is a neomorphic enzymatic activity that converts \u03b1-ketoglutarate to 2-hydroxyglutarate. Cancer Cell. 2010;17:225\u201334. https:\/\/doi.org\/10.1016\/j.ccr.2010.01.020.","journal-title":"Cancer Cell"},{"key":"1245_CR43","doi-asserted-by":"publisher","first-page":"19345","DOI":"10.1073\/pnas.0709747104","volume":"104","author":"RJ DeBerardinis","year":"2007","unstructured":"DeBerardinis RJ, Mancuso A, Daikhin E, Nissim I, Yudkoff M, Wehrli S, Thompson CB. Beyond aerobic glycolysis: transformed cells can engage in glutamine metabolism that exceeds the requirement for protein and nucleotide synthesis. Proc Natl Acad Sci USA. 2007;104:19345\u201350. https:\/\/doi.org\/10.1073\/pnas.0709747104.","journal-title":"Proc Natl Acad Sci USA"},{"key":"1245_CR44","doi-asserted-by":"publisher","first-page":"4393","DOI":"10.1021\/pr400403p","volume":"12","author":"Y Wang","year":"2013","unstructured":"Wang Y, Zhang L, Chen W-L, Wang J-H, Li N, Li J-M, Mi J-Q, Zhang W-N, Li Y, Wu S-F, Jin J, Wang Y-G, Huang H, Chen Z, Chen S-J, Tang H. Rapid diagnosis and prognosis of de novo acute myeloid leukemia by serum metabonomic analysis. J Proteome Res. 2013;12:4393\u2013401. https:\/\/doi.org\/10.1021\/pr400403p.","journal-title":"J Proteome Res"},{"key":"1245_CR45","first-page":"1159","volume":"31","author":"D Rudman","year":"1971","unstructured":"Rudman D, Vogler WR, Howard CH, Gerron GG. Observations on the plasma amino acids of patients with acute leukemia. Cancer Res. 1971;31:1159\u201365.","journal-title":"Cancer Res"},{"key":"1245_CR46","doi-asserted-by":"publisher","first-page":"357","DOI":"10.1016\/j.jpba.2019.01.022","volume":"166","author":"D Wang","year":"2019","unstructured":"Wang D, Tan G, Wang H, Chen P, Hao J, Wang Y. Identification of novel serum biomarker for the detection of acute myeloid leukemia based on liquid chromatography-mass spectrometry. J Pharm Biomed Anal. 2019;166:357\u201363. https:\/\/doi.org\/10.1016\/j.jpba.2019.01.022.","journal-title":"J Pharm Biomed Anal"},{"key":"1245_CR47","doi-asserted-by":"publisher","first-page":"3521","DOI":"10.1182\/blood-2013-03-493163","volume":"122","author":"L Willems","year":"2013","unstructured":"Willems L, Jacque N, Jacquel A, Neveux N, Maciel TT, Lambert M, Schmitt A, Poulain L, Green AS, Uzunov M, Kosmider O, Radford-Weiss I, Moura IC, Auberger P, Ifrah N, Bardet V, Chapuis N, Lacombe C, Mayeux P, Tamburini J, Bouscary D. Inhibiting glutamine uptake represents an attractive new strategy for treating acute myeloid leukemia. Blood. 2013;122:3521\u201332. https:\/\/doi.org\/10.1182\/blood-2013-03-493163.","journal-title":"Blood"},{"key":"1245_CR48","doi-asserted-by":"publisher","first-page":"79722","DOI":"10.18632\/oncotarget.12944","volume":"7","author":"P Matre","year":"2016","unstructured":"Matre P, Velez J, Jacamo R, Qi Y, Su X, Cai T, Chan SM, Lodi A, Sweeney SR, Ma H, Davis RE, Baran N, Haferlach T, Su X, Flores ER, Gonzalez D, Konoplev S, Samudio I, DiNardo C, Majeti R, Schimmer AD, Li W, Wang T, Tiziani S, Konopleva M. Inhibiting glutaminase in acute myeloid leukemia: metabolic dependency of selected AML subtypes. Oncotarget. 2016;7:79722\u201335. https:\/\/doi.org\/10.18632\/oncotarget.12944.","journal-title":"Oncotarget"},{"key":"1245_CR49","doi-asserted-by":"publisher","first-page":"247","DOI":"10.1016\/j.exphem.2013.12.001","volume":"42","author":"A Emadi","year":"2014","unstructured":"Emadi A, Jun SA, Tsukamoto T, Fathi AT, Minden MD, Dang CV. Inhibition of glutaminase selectively suppresses the growth of primary acute myeloid leukemia cells with IDH mutations. Exp Hematol. 2014;42:247\u201351. https:\/\/doi.org\/10.1016\/j.exphem.2013.12.001.","journal-title":"Exp Hematol"},{"key":"1245_CR50","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1016\/j.mito.2015.01.006","volume":"21","author":"NP Basak","year":"2015","unstructured":"Basak NP, Banerjee S. Mitochondrial dependency in progression of acute myeloid leukemia. Mitochondrion. 2015;21:41\u20138. https:\/\/doi.org\/10.1016\/j.mito.2015.01.006.","journal-title":"Mitochondrion"},{"key":"1245_CR51","doi-asserted-by":"publisher","first-page":"7897","DOI":"10.3390\/ijms23147897","volume":"23","author":"A Wagner","year":"2022","unstructured":"Wagner A, Kosnacova H, Chovanec M, Jurkovicova D. Mitochondrial genetic and epigenetic regulations in cancer: therapeutic potential. Int J Mol Sci. 2022;23:7897. https:\/\/doi.org\/10.3390\/ijms23147897.","journal-title":"Int J Mol Sci"},{"key":"1245_CR52","doi-asserted-by":"publisher","DOI":"10.3389\/fcell.2021.767510","volume":"9","author":"ND Sharma","year":"2021","unstructured":"Sharma ND, Keewan E, Matlawska-Wasowska K. Metabolic reprogramming and cell adhesion in acute leukemia adaptation to the CNS niche. Front Cell Dev Biol. 2021;9: 767510. https:\/\/doi.org\/10.3389\/fcell.2021.767510.","journal-title":"Front Cell Dev Biol"},{"key":"1245_CR53","doi-asserted-by":"publisher","first-page":"1566","DOI":"10.1016\/j.ccell.2022.10.004","volume":"40","author":"H Weng","year":"2022","unstructured":"Weng H, Huang F, Yu Z, Chen Z, Prince E, Kang Y, Zhou K, Li W, Hu J, Fu C, Aziz T, Li H, Li J, Yang Y, Han L, Zhang S, Ma Y, Sun M, Wu H, Zhang Z, Wunderlich M, Robinson S, Braas D, Hoeve JT, Zhang B, Marcucci G, Mulloy JC, Zhou K, Tao H-F, Deng X, Horne D, Wei M, Huang H, Chen J. The m6A reader IGF2BP2 regulates glutamine metabolism and represents a therapeutic target in acute myeloid leukemia. Cancer Cell. 2022;40:1566-1582.e10. https:\/\/doi.org\/10.1016\/j.ccell.2022.10.004.","journal-title":"Cancer Cell"},{"key":"1245_CR54","doi-asserted-by":"publisher","first-page":"432","DOI":"10.2174\/1568026618666180525100830","volume":"18","author":"M Song","year":"2018","unstructured":"Song M, Kim S-H, Im CY, Hwang H-J. Recent development of small molecule glutaminase inhibitors. Curr Top Med Chem. 2018;18:432\u201343. https:\/\/doi.org\/10.2174\/1568026618666180525100830.","journal-title":"Curr Top Med Chem"},{"key":"1245_CR55","doi-asserted-by":"publisher","first-page":"1346","DOI":"10.1182\/blood-2015-01-621870","volume":"126","author":"N Jacque","year":"2015","unstructured":"Jacque N, Ronchetti AM, Larrue C, Meunier G, Birsen R, Willems L, Saland E, Decroocq J, Maciel TT, Lambert M, Poulain L, Hospital MA, Sujobert P, Joseph L, Chapuis N, Lacombe C, Moura IC, Demo S, Sarry JE, Recher C, Mayeux P, Tamburini J, Bouscary D. Targeting glutaminolysis has antileukemic activity in acute myeloid leukemia and synergizes with BCL-2 inhibition. Blood. 2015;126:1346\u201356. https:\/\/doi.org\/10.1182\/blood-2015-01-621870.","journal-title":"Blood"},{"key":"1245_CR56","doi-asserted-by":"publisher","first-page":"131","DOI":"10.1039\/d2tb02194c","volume":"11","author":"H Mao","year":"2022","unstructured":"Mao H, Wen Y, Yu Y, Li H, Wang J, Sun B. Bioinspired nanocatalytic tumor therapy by simultaneous reactive oxygen species generation enhancement and glutamine pathway-mediated glutathione depletion. J Mater Chem B. 2022;11:131\u201343. https:\/\/doi.org\/10.1039\/d2tb02194c.","journal-title":"J Mater Chem B"},{"key":"1245_CR57","doi-asserted-by":"publisher","first-page":"436","DOI":"10.1080\/09553002.2018.1558299","volume":"95","author":"G Boysen","year":"2019","unstructured":"Boysen G, Jamshidi-Parsian A, Davis MA, Siegel ER, Kore RA, Dings RPM, Griffin RJ. Glutaminase inhibitor CB-839 increases radiation sensitivity of lung tumor cells and human lung tumor xenografts in mice. Int J Radiat Biol. 2019;95:436\u201342. https:\/\/doi.org\/10.1080\/09553002.2018.1558299.","journal-title":"Int J Radiat Biol"},{"key":"1245_CR58","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2022.889875","volume":"13","author":"M Romo-Gonz\u00e1lez","year":"2022","unstructured":"Romo-Gonz\u00e1lez M, Ijurko C, Hern\u00e1ndez-Hern\u00e1ndez \u00c1. Reactive oxygen species and metabolism in leukemia: a dangerous liaison. Front Immunol. 2022;13: 889875. https:\/\/doi.org\/10.3389\/fimmu.2022.889875.","journal-title":"Front Immunol"},{"key":"1245_CR59","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1016\/j.critrevonc.2017.02.004","volume":"112","author":"Y-F Chen","year":"2017","unstructured":"Chen Y-F, Liu H, Luo X-J, Zhao Z, Zou Z-Y, Li J, Lin X-J, Liang Y. The roles of reactive oxygen species (ROS) and autophagy in the survival and death of leukemia cells. Crit Rev Oncol Hematol. 2017;112:21\u201330. https:\/\/doi.org\/10.1016\/j.critrevonc.2017.02.004.","journal-title":"Crit Rev Oncol Hematol"},{"key":"1245_CR60","doi-asserted-by":"publisher","first-page":"805","DOI":"10.3390\/cells8080805","volume":"8","author":"J Kreitz","year":"2019","unstructured":"Kreitz J, Sch\u00f6nfeld C, Seibert M, Stolp V, Alshamleh I, Oellerich T, Steffen B, Schwalbe H, Schn\u00fctgen F, Kurrle N, Serve H. Metabolic plasticity of acute myeloid leukemia. Cells. 2019;8:805. https:\/\/doi.org\/10.3390\/cells8080805.","journal-title":"Cells"},{"key":"1245_CR61","doi-asserted-by":"publisher","first-page":"52","DOI":"10.1016\/j.exphem.2017.09.007","volume":"58","author":"MA Gregory","year":"2018","unstructured":"Gregory MA, Nemkov T, Reisz JA, Zaberezhnyy V, Hansen KC, D\u2019Alessandro A, DeGregori J. Glutaminase inhibition improves FLT3 inhibitor therapy for acute myeloid leukemia. Exp Hematol. 2018;58:52\u20138. https:\/\/doi.org\/10.1016\/j.exphem.2017.09.007.","journal-title":"Exp Hematol"},{"key":"1245_CR62","doi-asserted-by":"publisher","DOI":"10.1016\/j.exphem.2024.104253","author":"R Khamari","year":"2024","unstructured":"Khamari R, Degand C, Fovez Q, Trinh A, Chomy A, Laine W, Dekiouk S, Ghesquiere B, Quesnel B, Marchetti P, Manier S, Kluza PJ. Key role of glutamine metabolism in persistence of leukemic cells upon exposition to FLT3 tyrosine kinase inhibitors. Exp Hematol. 2024. https:\/\/doi.org\/10.1016\/j.exphem.2024.104253.","journal-title":"Exp Hematol"},{"key":"1245_CR63","doi-asserted-by":"publisher","first-page":"E6669","DOI":"10.1073\/pnas.1603876113","volume":"113","author":"MA Gregory","year":"2016","unstructured":"Gregory MA, D\u2019Alessandro A, Alvarez-Calderon F, Kim J, Nemkov T, Adane B, Rozhok AI, Kumar A, Kumar V, Pollyea DA, Wempe MF, Jordan CT, Serkova NJ, Tan AC, Hansen KC, DeGregori J. ATM\/G6PD-driven redox metabolism promotes FLT3 inhibitor resistance in acute myeloid leukemia. Proc Natl Acad Sci U S A. 2016;113:E6669\u201378. https:\/\/doi.org\/10.1073\/pnas.1603876113.","journal-title":"Proc Natl Acad Sci U S A"},{"key":"1245_CR64","doi-asserted-by":"publisher","first-page":"249","DOI":"10.1016\/j.nut.2003.11.018","volume":"20","author":"C Scheid","year":"2004","unstructured":"Scheid C, Hermann K, Kremer G, Holsing A, Heck G, Fuchs M, Waldschmidt D, Herrmann H-J, S\u00f6hngen D, Diehl V, Schwenk A. Randomized, double-blind, controlled study of glycyl-glutamine-dipeptide in the parenteral nutrition of patients with acute leukemia undergoing intensive chemotherapy. Nutr Burbank Los Angel Cty Calif. 2004;20:249\u201354. https:\/\/doi.org\/10.1016\/j.nut.2003.11.018.","journal-title":"Nutr Burbank Los Angel Cty Calif"},{"key":"1245_CR65","doi-asserted-by":"publisher","first-page":"1161254","DOI":"10.3389\/fonc.2023.1161254","volume":"13","author":"N Timofeeva","year":"2023","unstructured":"Timofeeva N, Ayres ML, Baran N, Santiago-O\u2019Farrill JM, Bildik G, Lu Z, Konopleva M, Gandhi V. Preclinical investigations of the efficacy of the glutaminase inhibitor CB-839 alone and in combinations in chronic lymphocytic leukemia. Front Oncol. 2023;13:1161254. https:\/\/doi.org\/10.3389\/fonc.2023.1161254.","journal-title":"Front Oncol"},{"key":"1245_CR66","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1038\/s41408-017-0039-2","volume":"8","author":"G Galicia-V\u00e1zquez","year":"2018","unstructured":"Galicia-V\u00e1zquez G, Smith S, Aloyz R. Del11q-positive CLL lymphocytes exhibit altered glutamine metabolism and differential response to GLS1 and glucose metabolism inhibition. Blood Cancer J. 2018;8:13. https:\/\/doi.org\/10.1038\/s41408-017-0039-2.","journal-title":"Blood Cancer J"},{"key":"1245_CR67","doi-asserted-by":"publisher","first-page":"2663","DOI":"10.1182\/blood-2013-10-532200","volume":"123","author":"R Jitschin","year":"2014","unstructured":"Jitschin R, Hofmann AD, Bruns H, Giessl A, Bricks J, Berger J, Saul D, Eckart MJ, Mackensen A, Mougiakakos D. Mitochondrial metabolism contributes to oxidative stress and reveals therapeutic targets in chronic lymphocytic leukemia. Blood. 2014;123:2663\u201372. https:\/\/doi.org\/10.1182\/blood-2013-10-532200.","journal-title":"Blood"},{"key":"1245_CR68","doi-asserted-by":"publisher","first-page":"528","DOI":"10.1182\/blood.2022016696","volume":"140","author":"S Deaglio","year":"2022","unstructured":"Deaglio S. Glutamine and CLL: ready for prime time? Blood. 2022;140:528\u20139. https:\/\/doi.org\/10.1182\/blood.2022016696.","journal-title":"Blood"},{"key":"1245_CR69","doi-asserted-by":"publisher","DOI":"10.1038\/bcj.2017.53","volume":"7","author":"T Terwilliger","year":"2017","unstructured":"Terwilliger T, Abdul-Hay M. Acute lymphoblastic leukemia: a comprehensive review and 2017 update. Blood Cancer J. 2017;7: e577. https:\/\/doi.org\/10.1038\/bcj.2017.53.","journal-title":"Blood Cancer J"},{"key":"1245_CR70","doi-asserted-by":"publisher","first-page":"83","DOI":"10.3322\/caac.21219","volume":"64","author":"E Ward","year":"2014","unstructured":"Ward E, DeSantis C, Robbins A, Kohler B, Jemal A. Childhood and adolescent cancer statistics, 2014. CA Cancer J Clin. 2014;64:83\u2013103. https:\/\/doi.org\/10.3322\/caac.21219.","journal-title":"CA Cancer J Clin"},{"key":"1245_CR71","first-page":"241","volume":"1","author":"VI Avramis","year":"2006","unstructured":"Avramis VI, Tiwari PN. Asparaginase (native ASNase or pegylated ASNase) in the treatment of acute lymphoblastic leukemia. Int J Nanomed. 2006;1:241\u201354.","journal-title":"Int J Nanomed"},{"key":"1245_CR72","doi-asserted-by":"publisher","first-page":"191","DOI":"10.1136\/bmj.1.5690.191","volume":"1","author":"ME Beard","year":"1970","unstructured":"Beard ME, Crowther D, Galton DA, Guyer RJ, Fairley GH, Kay HE, Knapton PJ, Malpas JS, Scott RB. L-asparaginase in treatment of acute leukaemia and lymphosarcoma. Br Med J. 1970;1:191\u20135. https:\/\/doi.org\/10.1136\/bmj.1.5690.191.","journal-title":"Br Med J"},{"key":"1245_CR73","doi-asserted-by":"publisher","first-page":"202","DOI":"10.1016\/j.ctrv.2010.08.002","volume":"37","author":"S Patil","year":"2011","unstructured":"Patil S, Coutsouvelis J, Spencer A. Asparaginase in the management of adult acute lymphoblastic leukaemia: is it used appropriately? Cancer Treat Rev. 2011;37:202\u20137. https:\/\/doi.org\/10.1016\/j.ctrv.2010.08.002.","journal-title":"Cancer Treat Rev"},{"key":"1245_CR74","doi-asserted-by":"publisher","first-page":"1412","DOI":"10.1002\/1878-0261.12877","volume":"15","author":"TL Nguyen","year":"2021","unstructured":"Nguyen TL, Nokin M-J, Ter\u00e9s S, Tom\u00e9 M, Bodineau C, Galmar O, Pasquet J-M, Rousseau B, van Liempd S, Falcon-Perez JM, Richard E, Muzotte E, Rezvani H-R, Priault M, Bouchecareilh M, Redonnet-Vernhet I, Calvo J, Uzan B, Pflumio F, Fuentes P, Toribio ML, Khatib A-M, Soubeyran P, Murdoch PDS, Dur\u00e1n RV. Downregulation of glutamine synthetase, not glutaminolysis, is responsible for glutamine addiction in Notch1-driven acute lymphoblastic leukemia. Mol Oncol. 2021;15:1412\u201331. https:\/\/doi.org\/10.1002\/1878-0261.12877.","journal-title":"Mol Oncol"},{"key":"1245_CR75","doi-asserted-by":"publisher","first-page":"2998","DOI":"10.1158\/0008-5472.CAN-12-4402","volume":"73","author":"EA Ehsanipour","year":"2013","unstructured":"Ehsanipour EA, Sheng X, Behan JW, Wang X, Butturini A, Avramis VI, Mittelman SD. Adipocytes cause leukemia cell resistance to L-asparaginase via release of glutamine. Cancer Res. 2013;73:2998\u20133006. https:\/\/doi.org\/10.1158\/0008-5472.CAN-12-4402.","journal-title":"Cancer Res"},{"key":"1245_CR76","doi-asserted-by":"publisher","first-page":"1014","DOI":"10.1182\/blood.2019001034","volume":"134","author":"Y Tabe","year":"2019","unstructured":"Tabe Y, Lorenzi PL, Konopleva M. Amino acid metabolism in hematologic malignancies and the era of targeted therapy. Blood. 2019;134:1014\u201323. https:\/\/doi.org\/10.1182\/blood.2019001034.","journal-title":"Blood"},{"key":"1245_CR77","first-page":"587","volume":"20","author":"JG Cory","year":"2006","unstructured":"Cory JG, Cory AH. Critical roles of glutamine as nitrogen donors in purine and pyrimidine nucleotide synthesis: asparaginase treatment in childhood acute lymphoblastic leukemia. Vivo Athens Greece. 2006;20:587\u20139.","journal-title":"Vivo Athens Greece"},{"key":"1245_CR78","doi-asserted-by":"publisher","first-page":"65","DOI":"10.1186\/s12937-016-0187-4","volume":"15","author":"Y Han","year":"2016","unstructured":"Han Y, Zhang F, Wang J, Zhu Y, Dai J, Bu Y, Yang Q, Xiao Y, Sun X. Application of Glutamine-enriched nutrition therapy in childhood acute lymphoblastic leukemia. Nutr J. 2016;15:65. https:\/\/doi.org\/10.1186\/s12937-016-0187-4.","journal-title":"Nutr J"},{"key":"1245_CR79","doi-asserted-by":"publisher","first-page":"1377","DOI":"10.1126\/science.1164266","volume":"322","author":"CG Mullighan","year":"2008","unstructured":"Mullighan CG, Phillips LA, Su X, Ma J, Miller CB, Shurtleff SA, Downing JR. Genomic analysis of the clonal origins of relapsed acute lymphoblastic leukemia. Science. 2008;322:1377\u201380. https:\/\/doi.org\/10.1126\/science.1164266.","journal-title":"Science"},{"key":"1245_CR80","doi-asserted-by":"publisher","first-page":"8348","DOI":"10.1074\/jbc.M114.618769","volume":"290","author":"C St\u00e4ubert","year":"2015","unstructured":"St\u00e4ubert C, Bhuiyan H, Lindahl A, Broom OJ, Zhu Y, Islam S, Linnarsson S, Lehti\u00f6 J, Nordstr\u00f6m A. Rewired metabolism in drug-resistant leukemia cells: a metabolic switch hallmarked by reduced dependence on exogenous glutamine. J Biol Chem. 2015;290:8348\u201359. https:\/\/doi.org\/10.1074\/jbc.M114.618769.","journal-title":"J Biol Chem"},{"key":"1245_CR81","doi-asserted-by":"publisher","first-page":"1616","DOI":"10.3390\/antiox10101616","volume":"10","author":"A Mannan","year":"2021","unstructured":"Mannan A, Germon ZP, Chamberlain J, Sillar JR, Nixon B, Dun MD. Reactive oxygen species in acute lymphoblastic leukaemia: reducing radicals to refine responses. Antioxid Basel Switz. 2021;10:1616. https:\/\/doi.org\/10.3390\/antiox10101616.","journal-title":"Antioxid Basel Switz"},{"key":"1245_CR82","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1097\/WOX.0b013e3182439613","volume":"5","author":"E Birben","year":"2012","unstructured":"Birben E, Sahiner UM, Sackesen C, Erzurum S, Kalayci O. Oxidative stress and antioxidant defense. World Allergy Organ J. 2012;5:9\u201319. https:\/\/doi.org\/10.1097\/WOX.0b013e3182439613.","journal-title":"World Allergy Organ J"},{"key":"1245_CR83","doi-asserted-by":"publisher","first-page":"1182","DOI":"10.1038\/nm.3955","volume":"21","author":"D Herranz","year":"2015","unstructured":"Herranz D, Ambesi-Impiombato A, Sudderth J, S\u00e1nchez-Mart\u00edn M, Belver L, Tosello V, Xu L, Wendorff AA, Castillo M, Haydu JE, M\u00e1rquez J, Mat\u00e9s JM, Kung AL, Rayport S, Cordon-Cardo C, DeBerardinis RJ, Ferrando AA. Metabolic reprogramming induces resistance to anti-NOTCH1 therapies in acute lymphoblastic leukemia. Nat Med. 2015;21:1182\u20139. https:\/\/doi.org\/10.1038\/nm.3955.","journal-title":"Nat Med"},{"key":"1245_CR84","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2022.960226","volume":"13","author":"T Sancerni","year":"2022","unstructured":"Sancerni T, Renoult O, Luby A, Caradeuc C, Lenoir V, Croyal M, Ransy C, Aguilar E, Postic C, Bertho G, Dentin R, Prip-Buus C, Pecqueur C, Alves-Guerra M-C. UCP2 silencing restrains leukemia cell proliferation through glutamine metabolic remodeling. Front Immunol. 2022;13: 960226. https:\/\/doi.org\/10.3389\/fimmu.2022.960226.","journal-title":"Front Immunol"},{"key":"1245_CR85","doi-asserted-by":"publisher","first-page":"1373","DOI":"10.1038\/s42255-020-00315-1","volume":"2","author":"S Raho","year":"2020","unstructured":"Raho S, Capobianco L, Malivindi R, Vozza A, Piazzolla C, De Leonardis F, Gorgoglione R, Scarcia P, Pezzuto F, Agrimi G, Barile SN, Pisano I, Reshkin SJ, Greco MR, Cardone RA, Rago V, Li Y, Marobbio CMT, Sommergruber W, Riley CL, Lasorsa FM, Mills E, Vegliante MC, De Benedetto GE, Fratantonio D, Palmieri L, Dolce V, Fiermonte G. KRAS-regulated glutamine metabolism requires UCP2-mediated aspartate transport to support pancreatic cancer growth. Nat Metab. 2020;2:1373\u201381. https:\/\/doi.org\/10.1038\/s42255-020-00315-1.","journal-title":"Nat Metab"},{"key":"1245_CR86","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbcan.2023.188890","volume":"1878","author":"Y Liu","year":"2023","unstructured":"Liu Y, Wan Y, Jiang Y, Zhang L, Cheng W. GPX4: The hub of lipid oxidation, ferroptosis, disease and treatment. Biochim Biophys Acta Rev Cancer. 2023;1878: 188890. https:\/\/doi.org\/10.1016\/j.bbcan.2023.188890.","journal-title":"Biochim Biophys Acta Rev Cancer"},{"key":"1245_CR87","doi-asserted-by":"publisher","first-page":"266","DOI":"10.1038\/s41580-020-00324-8","volume":"22","author":"X Jiang","year":"2021","unstructured":"Jiang X, Stockwell BR, Conrad M. Ferroptosis: mechanisms, biology and role in disease. Nat Rev Mol Cell Biol. 2021;22:266\u201382. https:\/\/doi.org\/10.1038\/s41580-020-00324-8.","journal-title":"Nat Rev Mol Cell Biol"},{"key":"1245_CR88","doi-asserted-by":"publisher","first-page":"449","DOI":"10.3390\/ijms24010449","volume":"24","author":"L Rochette","year":"2022","unstructured":"Rochette L, Dogon G, Rigal E, Zeller M, Cottin Y, Vergely C. Lipid Peroxidation and iron metabolism: two corner stones in the homeostasis control of ferroptosis. Int J Mol Sci. 2022;24:449. https:\/\/doi.org\/10.3390\/ijms24010449.","journal-title":"Int J Mol Sci"},{"key":"1245_CR89","doi-asserted-by":"publisher","first-page":"39527","DOI":"10.1074\/jbc.M304423200","volume":"278","author":"K Chen","year":"2003","unstructured":"Chen K, Albano A, Ho A, Keaney JF. Activation of p53 by oxidative stress involves platelet-derived growth factor-beta receptor-mediated ataxia telangiectasia mutated (ATM) kinase activation. J Biol Chem. 2003;278:39527\u201333. https:\/\/doi.org\/10.1074\/jbc.M304423200.","journal-title":"J Biol Chem"},{"key":"1245_CR90","doi-asserted-by":"publisher","first-page":"4900","DOI":"10.1111\/jcmm.14511","volume":"23","author":"T Xu","year":"2019","unstructured":"Xu T, Ding W, Ji X, Ao X, Liu Y, Yu W, Wang J. Molecular mechanisms of ferroptosis and its role in cancer therapy. J Cell Mol Med. 2019;23:4900\u201312. https:\/\/doi.org\/10.1111\/jcmm.14511.","journal-title":"J Cell Mol Med"},{"key":"1245_CR91","doi-asserted-by":"publisher","first-page":"49","DOI":"10.1038\/s41392-020-00428-9","volume":"6","author":"H-F Yan","year":"2021","unstructured":"Yan H-F, Zou T, Tuo Q-Z, Xu S, Li H, Belaidi AA, Lei P. Ferroptosis: mechanisms and links with diseases. Signal Transduct Target Ther. 2021;6:49. https:\/\/doi.org\/10.1038\/s41392-020-00428-9.","journal-title":"Signal Transduct Target Ther"},{"key":"1245_CR92","doi-asserted-by":"publisher","first-page":"298","DOI":"10.1016\/j.molcel.2015.06.011","volume":"59","author":"M Gao","year":"2015","unstructured":"Gao M, Monian P, Quadri N, Ramasamy R, Jiang X. Glutaminolysis and transferrin regulate ferroptosis. Mol Cell. 2015;59:298\u2013308. https:\/\/doi.org\/10.1016\/j.molcel.2015.06.011.","journal-title":"Mol Cell"},{"key":"1245_CR93","doi-asserted-by":"publisher","first-page":"8788","DOI":"10.1073\/pnas.1003428107","volume":"107","author":"F Weinberg","year":"2010","unstructured":"Weinberg F, Hamanaka R, Wheaton WW, Weinberg S, Joseph J, Lopez M, Kalyanaraman B, Mutlu GM, Budinger GRS, Chandel NS. Mitochondrial metabolism and ROS generation are essential for Kras-mediated tumorigenicity. Proc Natl Acad Sci USA. 2010;107:8788\u201393. https:\/\/doi.org\/10.1073\/pnas.1003428107.","journal-title":"Proc Natl Acad Sci USA"},{"key":"1245_CR94","doi-asserted-by":"publisher","first-page":"216","DOI":"10.1007\/s13238-017-0451-1","volume":"9","author":"NM Anderson","year":"2018","unstructured":"Anderson NM, Mucka P, Kern JG, Feng H. The emerging role and targetability of the TCA cycle in cancer metabolism. Protein Cell. 2018;9:216\u201337. https:\/\/doi.org\/10.1007\/s13238-017-0451-1.","journal-title":"Protein Cell"},{"key":"1245_CR95","doi-asserted-by":"publisher","DOI":"10.1038\/cddis.2016.105","volume":"7","author":"E Panieri","year":"2016","unstructured":"Panieri E, Santoro MM. ROS homeostasis and metabolism: a dangerous liason in cancer cells. Cell Death Dis. 2016;7: e2253. https:\/\/doi.org\/10.1038\/cddis.2016.105.","journal-title":"Cell Death Dis"},{"key":"1245_CR96","doi-asserted-by":"publisher","first-page":"354","DOI":"10.1016\/j.molcel.2018.10.042","volume":"73","author":"M Gao","year":"2019","unstructured":"Gao M, Yi J, Zhu J, Minikes AM, Monian P, Thompson CB, Jiang X. Role of mitochondria in ferroptosis. Mol Cell. 2019;73:354-363.e3. https:\/\/doi.org\/10.1016\/j.molcel.2018.10.042.","journal-title":"Mol Cell"},{"key":"1245_CR97","doi-asserted-by":"publisher","first-page":"5566","DOI":"10.3390\/cancers15235566","volume":"15","author":"J Buczkowska","year":"2023","unstructured":"Buczkowska J, Szeliga M. Two faces of glutaminase GLS2 in carcinogenesis. Cancers. 2023;15:5566. https:\/\/doi.org\/10.3390\/cancers15235566.","journal-title":"Cancers"},{"key":"1245_CR98","doi-asserted-by":"publisher","first-page":"3209","DOI":"10.1158\/0008-5472.CAN-21-3914","volume":"82","author":"S Suzuki","year":"2022","unstructured":"Suzuki S, Venkatesh D, Kanda H, Nakayama A, Hosokawa H, Lee E, Miki T, Stockwell BR, Yokote K, Tanaka T, Prives C. GLS2 is a tumor suppressor and a regulator of ferroptosis in hepatocellular carcinoma. Cancer Res. 2022;82:3209\u201322. https:\/\/doi.org\/10.1158\/0008-5472.CAN-21-3914.","journal-title":"Cancer Res"},{"key":"1245_CR99","doi-asserted-by":"publisher","first-page":"900","DOI":"10.18632\/oncotarget.28526","volume":"14","author":"S Suzuki","year":"2023","unstructured":"Suzuki S, Venkatesh D, Tanaka T, Prives C. GLS2 shapes ferroptosis in hepatocellular carcinoma. Oncotarget. 2023;14:900\u20133. https:\/\/doi.org\/10.18632\/oncotarget.28526.","journal-title":"Oncotarget"},{"key":"1245_CR100","doi-asserted-by":"publisher","first-page":"349","DOI":"10.1016\/j.molcel.2012.05.043","volume":"47","author":"RV Dur\u00e1n","year":"2012","unstructured":"Dur\u00e1n RV, Oppliger W, Robitaille AM, Heiserich L, Skendaj R, Gottlieb E, Hall MN. Glutaminolysis activates Rag-mTORC1 signaling. Mol Cell. 2012;47:349\u201358. https:\/\/doi.org\/10.1016\/j.molcel.2012.05.043.","journal-title":"Mol Cell"},{"key":"1245_CR101","doi-asserted-by":"publisher","first-page":"643","DOI":"10.1002\/hep.30876","volume":"71","author":"L Wang","year":"2020","unstructured":"Wang L, Zhu L, Wu K, Chen Y, Lee D-Y, Gucek M, Sack MN. Mitochondrial general control of amino acid synthesis 5 Like 1 regulates glutaminolysis, mTORC1 activity and murine liver regeneration. Hepatol Baltim Md. 2020;71:643\u201357. https:\/\/doi.org\/10.1002\/hep.30876.","journal-title":"Hepatol Baltim Md"},{"key":"1245_CR102","doi-asserted-by":"publisher","DOI":"10.1083\/jcb.202208103","volume":"221","author":"J Zhu","year":"2022","unstructured":"Zhu J, Wang H, Jiang X. mTORC1 beyond anabolic metabolism: regulation of cell death. J Cell Biol. 2022;221: e202208103. https:\/\/doi.org\/10.1083\/jcb.202208103.","journal-title":"J Cell Biol"},{"key":"1245_CR103","doi-asserted-by":"publisher","first-page":"1589","DOI":"10.1038\/s41467-021-21841-w","volume":"12","author":"Y Zhang","year":"2021","unstructured":"Zhang Y, Swanda RV, Nie L, Liu X, Wang C, Lee H, Lei G, Mao C, Koppula P, Cheng W, Zhang J, Xiao Z, Zhuang L, Fang B, Chen J, Qian S-B, Gan B. mTORC1 couples cyst(e)ine availability with GPX4 protein synthesis and ferroptosis regulation. Nat Commun. 2021;12:1589. https:\/\/doi.org\/10.1038\/s41467-021-21841-w.","journal-title":"Nat Commun"},{"key":"1245_CR104","doi-asserted-by":"publisher","DOI":"10.7554\/eLife.56749","volume":"9","author":"H Jin","year":"2020","unstructured":"Jin H, Wang S, Zaal EA, Wang C, Wu H, Bosma A, Jochems F, Isima N, Jin G, Lieftink C, Beijersbergen R, Berkers CR, Qin W, Bernards R. A powerful drug combination strategy targeting glutamine addiction for the treatment of human liver cancer. Elife. 2020;9: e56749. https:\/\/doi.org\/10.7554\/eLife.56749.","journal-title":"Elife"},{"key":"1245_CR105","doi-asserted-by":"publisher","first-page":"685","DOI":"10.19746\/j.cnki.issn.1009-2137.2021.03.005","volume":"29","author":"Q-Q Li","year":"2021","unstructured":"Li Q-Q, Pan S-Y, Chen Q-Y, Zhou W, Wang S-Q. Effect of competitive antagonist of transmembrane glutamine flux V-9302 on apoptosis of acute myeloid leukemia cell lines HL-60 and KG-1. Zhongguo Shi Yan Xue Ye Xue Za Zhi. 2021;29:685\u20139. https:\/\/doi.org\/10.19746\/j.cnki.issn.1009-2137.2021.03.005.","journal-title":"Zhongguo Shi Yan Xue Ye Xue Za Zhi"},{"key":"1245_CR106","doi-asserted-by":"publisher","first-page":"20322","DOI":"10.1002\/jcp.28632","volume":"234","author":"Y Li","year":"2019","unstructured":"Li Y, Shao H, Da Z, Pan J, Fu B. High expression of SLC38A1 predicts poor prognosis in patients with de novo acute myeloid leukemia. J Cell Physiol. 2019;234:20322\u20138. https:\/\/doi.org\/10.1002\/jcp.28632.","journal-title":"J Cell Physiol"},{"key":"1245_CR107","doi-asserted-by":"publisher","first-page":"891","DOI":"10.1038\/s41598-018-37385-x","volume":"9","author":"A Corti","year":"2019","unstructured":"Corti A, Dominici S, Piaggi S, Belcastro E, Chiu M, Taurino G, Pacini S, Bussolati O, Pompella A. \u03b3-Glutamyltransferase enzyme activity of cancer cells modulates L-\u03b3-glutamyl-p-nitroanilide (GPNA) cytotoxicity. Sci Rep. 2019;9:891. https:\/\/doi.org\/10.1038\/s41598-018-37385-x.","journal-title":"Sci Rep"},{"key":"1245_CR108","doi-asserted-by":"publisher","first-page":"217","DOI":"10.1007\/s00280-017-3459-6","volume":"81","author":"A Emadi","year":"2018","unstructured":"Emadi A, Law JY, Strovel ET, Lapidus RG, Jeng LJB, Lee M, Blitzer MG, Carter-Cooper BA, Sewell D, Van Der Merwe I, Philip S, Imran M, Yu SL, Li H, Amrein PC, Duong VH, Sausville EA, Baer MR, Fathi AT, Singh Z, Bentzen SM. Asparaginase Erwinia chrysanthemi effectively depletes plasma glutamine in adult patients with relapsed\/refractory acute myeloid leukemia. Cancer Chemother Pharmacol. 2018;81:217\u201322. https:\/\/doi.org\/10.1007\/s00280-017-3459-6.","journal-title":"Cancer Chemother Pharmacol"},{"key":"1245_CR109","doi-asserted-by":"publisher","first-page":"2207","DOI":"10.1158\/1535-7163.MCT-21-0071","volume":"20","author":"ME Zavorka Thomas","year":"2021","unstructured":"Zavorka Thomas ME, Lu X, Talebi Z, Jeon JY, Buelow DR, Gibson AA, Uddin ME, Brinton LT, Nguyen J, Collins M, Lodi A, Sweeney SR, Campbell MJ, Sweet DH, Sparreboom A, Lapalombella R, Tiziani S, Baker SD. Gilteritinib inhibits glutamine uptake and utilization in FLT3-ITD-positive AML. Mol Cancer Ther. 2021;20:2207\u201317. https:\/\/doi.org\/10.1158\/1535-7163.MCT-21-0071.","journal-title":"Mol Cancer Ther"},{"key":"1245_CR110","doi-asserted-by":"publisher","DOI":"10.21203\/rs.3.rs-2518774\/v1","author":"M Konopleva","year":"2023","unstructured":"Konopleva M, DiNardo C, Bhagat T, Baran N, Lodi A, Saxena K, Cai T, Su X, Skwarska A, Guerra V, Kuruvilla V, Konoplev S, Gordon-Mitchell S, Pradhan K, Aluri S, Collins M, Sweeney S, Busquet J, Rathore A, Deng Q, Green M, Grant S, Demo S, Choudhary G, Sahu S, Agarwal B, Spodek M, Thiruthuvanathan V, Will B, Steidl U, Tippett G, Burger J, Borthakur G, Jabbour E, Pemmaraju N, Kadia T, Kornblau S, Daver N, Naqvi K, Short N, Garcia-Manero G, Tiziani S, Verma A. Glutaminase inhibition in combination with azacytidine in myelodysplastic syndromes: clinical efficacy and correlative analyses. Res Sq. 2023. https:\/\/doi.org\/10.21203\/rs.3.rs-2518774\/v1.","journal-title":"Res Sq"},{"key":"1245_CR111","doi-asserted-by":"publisher","first-page":"1824","DOI":"10.1158\/1535-7163.MCT-17-1148","volume":"17","author":"KM Lemberg","year":"2018","unstructured":"Lemberg KM, Vornov JJ, Rais R, Slusher BS. We\u2019re not \u201cDON\u201d yet: optimal dosing and prodrug delivery of 6-Diazo-5-oxo-L-norleucine. Mol Cancer Ther. 2018;17:1824\u201332. https:\/\/doi.org\/10.1158\/1535-7163.MCT-17-1148.","journal-title":"Mol Cancer Ther"},{"key":"1245_CR112","doi-asserted-by":"publisher","first-page":"1314","DOI":"10.1016\/j.tranon.2019.05.013","volume":"12","author":"AR Hanaford","year":"2019","unstructured":"Hanaford AR, Alt J, Rais R, Wang SZ, Kaur H, Thorek DLJ, Eberhart CG, Slusher BS, Martin AM, Raabe EH. Orally bioavailable glutamine antagonist prodrug JHU-083 penetrates mouse brain and suppresses the growth of MYC-driven medulloblastoma. Transl Oncol. 2019;12:1314\u201322. https:\/\/doi.org\/10.1016\/j.tranon.2019.05.013.","journal-title":"Transl Oncol"},{"key":"1245_CR113","doi-asserted-by":"publisher","first-page":"1907","DOI":"10.1038\/s41375-020-01080-6","volume":"35","author":"A Emadi","year":"2021","unstructured":"Emadi A, Kapadia B, Bollino D, Bhandary B, Baer MR, Niyongere S, Strovel ET, Kaizer H, Chang E, Choi EY, Ma X, Tighe KM, Carter-Cooper B, Moses BS, Civin CI, Mahurkar A, Shetty AC, Gartenhaus RB, Kamangar F, Lapidus RG. Venetoclax and pegcrisantaspase for complex karyotype acute myeloid leukemia. Leukemia. 2021;35:1907\u201324. https:\/\/doi.org\/10.1038\/s41375-020-01080-6.","journal-title":"Leukemia"},{"key":"1245_CR114","doi-asserted-by":"publisher","first-page":"420","DOI":"10.1111\/bjh.15920","volume":"186","author":"IM Michelozzi","year":"2019","unstructured":"Michelozzi IM, Granata V, De Ponti G, Alberti G, Tomasoni C, Antolini L, Gambacorti-Passerini C, Gentner B, Dazzi F, Biondi A, Coliva T, Rizzari C, Pievani A, Serafini M. Acute myeloid leukaemia niche regulates response to L-asparaginase. Br J Haematol. 2019;186:420\u201330. https:\/\/doi.org\/10.1111\/bjh.15920.","journal-title":"Br J Haematol"},{"key":"1245_CR115","doi-asserted-by":"publisher","first-page":"1509","DOI":"10.1016\/0006-2952(82)90373-2","volume":"31","author":"B Ardalan","year":"1982","unstructured":"Ardalan B, Arakawa M, Villacorte D, Jayaram H, Cooney DA. Effect of L-glutamine antagonists on 5-phosphoribosyl 1-pyrophosphate levels in P388 leukemia and in murine colon adenocarcinomas in vivo. Biochem Pharmacol. 1982;31:1509\u201313. https:\/\/doi.org\/10.1016\/0006-2952(82)90373-2.","journal-title":"Biochem Pharmacol"},{"key":"1245_CR116","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2022.931393","volume":"12","author":"F Zuo","year":"2022","unstructured":"Zuo F, Yu J, He X. Single-cell metabolomics in hematopoiesis and hematological malignancies. Front Oncol. 2022;12: 931393. https:\/\/doi.org\/10.3389\/fonc.2022.931393.","journal-title":"Front Oncol"},{"key":"1245_CR117","doi-asserted-by":"publisher","first-page":"1765","DOI":"10.18632\/oncotarget.6426","volume":"7","author":"F Polet","year":"2016","unstructured":"Polet F, Corbet C, Pinto A, Rubio LI, Martherus R, Bol V, Drozak X, Gr\u00e9goire V, Riant O, Feron O. Reducing the serine availability complements the inhibition of the glutamine metabolism to block leukemia cell growth. Oncotarget. 2016;7:1765\u201376. https:\/\/doi.org\/10.18632\/oncotarget.6426.","journal-title":"Oncotarget"},{"key":"1245_CR118","doi-asserted-by":"publisher","first-page":"332","DOI":"10.1016\/j.molmed.2020.10.001","volume":"27","author":"R Culp-Hill","year":"2021","unstructured":"Culp-Hill R, D\u2019Alessandro A, Pietras EM. Extinguishing the embers: targeting AML metabolism. Trends Mol Med. 2021;27:332\u201344. https:\/\/doi.org\/10.1016\/j.molmed.2020.10.001.","journal-title":"Trends Mol Med"},{"key":"1245_CR119","doi-asserted-by":"publisher","first-page":"329","DOI":"10.1016\/j.stem.2012.12.013","volume":"12","author":"ED Lagadinou","year":"2013","unstructured":"Lagadinou ED, Sach A, Callahan K, Rossi RM, Neering SJ, Minhajuddin M, Ashton JM, Pei S, Grose V, O\u2019Dwyer KM, Liesveld JL, Brookes PS, Becker MW, Jordan CT. BCL-2 inhibition targets oxidative phosphorylation and selectively eradicates quiescent human leukemia stem cells. Cell Stem Cell. 2013;12:329\u201341. https:\/\/doi.org\/10.1016\/j.stem.2012.12.013.","journal-title":"Cell Stem Cell"},{"key":"1245_CR120","doi-asserted-by":"publisher","first-page":"716","DOI":"10.1158\/2159-8290.CD-16-0441","volume":"7","author":"T Farge","year":"2017","unstructured":"Farge T, Saland E, de Toni F, Aroua N, Hosseini M, Perry R, Bosc C, Sugita M, Stuani L, Fraisse M, Scotland S, Larrue C, Boutzen H, F\u00e9liu V, Nicolau-Travers M-L, Cassant-Sourdy S, Broin N, David M, Serhan N, Sarry A, Tavitian S, Kaoma T, Vallar L, Iacovoni J, Linares LK, Montersino C, Castellano R, Griessinger E, Collette Y, Duchamp O, Barreira Y, Hirsch P, Palama T, Gales L, Delhommeau F, Garmy-Susini BH, Portais J-C, Vergez F, Selak M, Danet-Desnoyers G, Carroll M, R\u00e9cher C, Sarry J-E. Chemotherapy-resistant human acute myeloid leukemia cells are not enriched for leukemic stem cells but require oxidative metabolism. Cancer Discov. 2017;7:716\u201335. https:\/\/doi.org\/10.1158\/2159-8290.CD-16-0441.","journal-title":"Cancer Discov"},{"key":"1245_CR121","doi-asserted-by":"publisher","first-page":"155","DOI":"10.3389\/fonc.2020.00155","volume":"10","author":"Y Tabe","year":"2020","unstructured":"Tabe Y, Konopleva M, Andreeff M. Fatty acid metabolism, bone marrow adipocytes, and AML. Front Oncol. 2020;10:155. https:\/\/doi.org\/10.3389\/fonc.2020.00155.","journal-title":"Front Oncol"},{"key":"1245_CR122","doi-asserted-by":"publisher","first-page":"732","DOI":"10.1038\/nrc.2016.89","volume":"16","author":"F R\u00f6hrig","year":"2016","unstructured":"R\u00f6hrig F, Schulze A. The multifaceted roles of fatty acid synthesis in cancer. Nat Rev Cancer. 2016;16:732\u201349. https:\/\/doi.org\/10.1038\/nrc.2016.89.","journal-title":"Nat Rev Cancer"},{"key":"1245_CR123","doi-asserted-by":"publisher","DOI":"10.1038\/oncsis.2015.49","volume":"5","author":"S Beloribi-Djefaflia","year":"2016","unstructured":"Beloribi-Djefaflia S, Vasseur S, Guillaumond F. Lipid metabolic reprogramming in cancer cells. Oncogenesis. 2016;5: e189. https:\/\/doi.org\/10.1038\/oncsis.2015.49.","journal-title":"Oncogenesis"},{"key":"1245_CR124","doi-asserted-by":"publisher","first-page":"1007","DOI":"10.1016\/j.cmet.2018.03.002","volume":"27","author":"Q Chen","year":"2018","unstructured":"Chen Q, Kirk K, Shurubor YI, Zhao D, Arreguin AJ, Shahi I, Valsecchi F, Primiano G, Calder EL, Carelli V, Denton TT, Beal FM, Gross SS, Manfredi G, D\u2019Aurelio M. Rewiring of glutamine metabolism is a bioenergetic adaptation of human cells with mitochondrial DNA mutations. Cell Metab. 2018;27:1007-1025.e5. https:\/\/doi.org\/10.1016\/j.cmet.2018.03.002.","journal-title":"Cell Metab"},{"key":"1245_CR125","doi-asserted-by":"publisher","first-page":"46371","DOI":"10.18632\/oncotarget.10131","volume":"7","author":"F Polet","year":"2016","unstructured":"Polet F, Martherus R, Corbet C, Pinto A, Feron O. Inhibition of glucose metabolism prevents glycosylation of the glutamine transporter ASCT2 and promotes compensatory LAT1 upregulation in leukemia cells. Oncotarget. 2016;7:46371\u201383. https:\/\/doi.org\/10.18632\/oncotarget.10131.","journal-title":"Oncotarget"},{"key":"1245_CR126","doi-asserted-by":"publisher","first-page":"391","DOI":"10.1016\/j.cmet.2020.07.009","volume":"32","author":"N van Gastel","year":"2020","unstructured":"van Gastel N, Spinelli JB, Sharda A, Schajnovitz A, Baryawno N, Rhee C, Oki T, Grace E, Soled HJ, Milosevic J, Sykes DB, Hsu PP, Vander Heiden MG, Vidoudez C, Trauger SA, Haigis MC, Scadden DT. Induction of a timed metabolic collapse to overcome cancer chemoresistance. Cell Metab. 2020;32:391-403.e6. https:\/\/doi.org\/10.1016\/j.cmet.2020.07.009.","journal-title":"Cell Metab"},{"key":"1245_CR127","doi-asserted-by":"publisher","first-page":"114","DOI":"10.1186\/s12964-022-00909-0","volume":"20","author":"G Ma","year":"2022","unstructured":"Ma G, Zhang Z, Li P, Zhang Z, Zeng M, Liang Z, Li D, Wang L, Chen Y, Liang Y, Niu H. Reprogramming of glutamine metabolism and its impact on immune response in the tumor microenvironment. Cell Commun Signal CCS. 2022;20:114. https:\/\/doi.org\/10.1186\/s12964-022-00909-0.","journal-title":"Cell Commun Signal CCS"},{"key":"1245_CR128","doi-asserted-by":"publisher","first-page":"1383","DOI":"10.1177\/147323000803600628","volume":"36","author":"C Sornsuvit","year":"2008","unstructured":"Sornsuvit C, Komindr S, Chuncharunee S, Wanikiat P, Archararit N, Santanirand P. Pilot Study: effects of parenteral glutamine dipeptide supplementation on neutrophil functions and prevention of chemotherapy-induced side-effects in acute myeloid leukaemia patients. J Int Med Res. 2008;36:1383\u201391. https:\/\/doi.org\/10.1177\/147323000803600628.","journal-title":"J Int Med Res"},{"key":"1245_CR129","doi-asserted-by":"publisher","first-page":"985","DOI":"10.1038\/ni.3796","volume":"18","author":"P-S Liu","year":"2017","unstructured":"Liu P-S, Wang H, Li X, Chao T, Teav T, Christen S, Di Conza G, Cheng W-C, Chou C-H, Vavakova M, Muret C, Debackere K, Mazzone M, Huang H-D, Fendt S-M, Ivanisevic J, Ho P-C. \u03b1-ketoglutarate orchestrates macrophage activation through metabolic and epigenetic reprogramming. Nat Immunol. 2017;18:985\u201394. https:\/\/doi.org\/10.1038\/ni.3796.","journal-title":"Nat Immunol"}],"container-title":["Discover Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12672-024-01245-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s12672-024-01245-0\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12672-024-01245-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,9,3]],"date-time":"2024-09-03T14:24:19Z","timestamp":1725373459000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s12672-024-01245-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,8,31]]},"references-count":129,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2024,12]]}},"alternative-id":["1245"],"URL":"https:\/\/doi.org\/10.1007\/s12672-024-01245-0","relation":{},"ISSN":["2730-6011"],"issn-type":[{"value":"2730-6011","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,8,31]]},"assertion":[{"value":"25 March 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"14 August 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"31 August 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This article is based on previously conducted studies and does not contain any new studies with human participants or animals performed by any of the authors.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"The authors declare no competing interests.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"391"}}